CD4 and acute myeloid leukemia: The percentage of cytotoxic CD4+Teff varied among AML patients (Fig. 2c), sharing a low proportion in most AML patients, except in AML4 and AML5, suggesting that the enhanced functions of various cells are involved in exerting immune effects [22].